Method for determining blood drug level of mizoribine

A technology for plasma drug concentration and mizoribine, which is applied in the field of medical testing, can solve the problems of unsuitable drug concentration monitoring, cumbersome and time-consuming operation, and high analysis cost, and achieves a simple pretreatment method, a fast and accurate method, and a small amount of plasma. Effect

Inactive Publication Date: 2006-07-19
AFFILIATED HUSN HOSPITAL OF FUDAN UNIV
View PDF0 Cites 4 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

Existing technical methods have low sensitivity (lowest limit of quantification is 0.25mg L -1 ), cumbersome and time-consuming operation, low efficiency, high analysis cost and other defects, it is not suitable for routine therapeutic drug concentration monitoring

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Method for determining blood drug level of mizoribine
  • Method for determining blood drug level of mizoribine

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0023] Chromatographic conditions

[0024] Column: Phenomenex Luna NH 2 (4.6mm×250mm, 5μm, Phenomenex, USA); mobile phase: acetonitrile-methanol-0.1% trifluoroacetic acid (85:5:10); flow rate: 1.5mL·min -1 ; Column temperature: 30℃; Detection wavelength, 280nm.

[0025] Plasma sample pretreatment

[0026] Take 100 μL of plasma sample, add 100 μL of acetonitrile solution, vortex for 20 s, centrifuge at 12000×g for 10 min at 4°C, and take 20 μL of supernatant for injection. The external standard method was quantified by peak area.

[0027] exclusivity

[0028] The blood samples of 10 kidney transplant patients who did not take MZR from different sources were taken and measured according to the above sample pretreatment and measurement methods. The results showed that no endogenous substances were found to interfere with the above measured components. The commonly used concomitant drugs and over-the-counter drug reference solutions were injected. , ibuprofen, acyclovir, etc...

Embodiment 2

[0036] Chromatographic conditions

[0037] Column: Phenomenex Luna NH 2 (4.6mm×250mm, 5μm, Phenomenex, USA); mobile phase: acetonitrile-methanol-0.1% trifluoroacetic acid (85:5:10); flow rate: 1.5mL·min -1 ; Column temperature: 30℃; Detection wavelength, 280nm.

[0038] Plasma sample pretreatment

[0039] Take 100 μL of plasma sample, add 100 μL of a mixture of acetonitrile and methanol (1:1, V / V), vortex for 20 s, centrifuge at 12,000 × g for 10 min at 4°C, and take 20 μL of supernatant for injection. The external standard method was quantified by peak area.

[0040] exclusivity

[0041] Blood samples were taken from 10 kidney transplant patients who did not take MZR, and the samples were pretreated and measured according to the above-mentioned methods. In addition, the commonly used concomitant drugs and over-the-counter drug reference solutions were injected. Results showed endogenous substances, cyclosporine, prednisone, tamoxifen, sirolimus, ganciclovir, betaloc, ac...

Embodiment 3

[0047] Chromatographic conditions

[0048] Column: Phenomenex Luna NH 2(4.6mm×250mm, 5μm, Phenomenex, USA); mobile phase: acetonitrile-methanol-0.1% trifluoroacetic acid (85:5:10); flow rate: 1.5mL·min -1 ; Column temperature: 30℃; Detection wavelength, 280nm.

[0049] Plasma sample pretreatment

[0050] Take 100 μL of plasma sample, add 200 μL of methanol solution, vortex for 20 s, centrifuge at 12000×g for 10 min at 4°C, and take 30 μL of supernatant for injection. The external standard method was quantified by peak area.

[0051] exclusivity

[0052] Blood samples were taken from 10 kidney transplant patients who did not take MZR, and the samples were pretreated and measured according to the above-mentioned methods. In addition, the commonly used concomitant drugs and over-the-counter drug reference solutions were injected. Results showed endogenous substances, cyclosporine, prednisone, tamoxifen, sirolimus, ganciclovir, betaloc, acetaminophen, nifedipine, ibuprofen, ...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

PropertyMeasurementUnit
Sensitivityaaaaaaaaaa
linear rangeaaaaaaaaaa
Login to view more

Abstract

The invention relates to an internal drug assay determination method in the field of medical examination, which relates to a method for measuring human plasma imidazole density. It dose equal indicative elution on acid traveling phase condition after doing first treatment to the tested sample by protein depositing and uses ultraviolet detector to test it after chromatographic column separating.

Description

technical field [0001] The invention belongs to the field of medical testing, and relates to a method for analyzing and measuring drugs in vivo. Specifically, it relates to a method for determining the blood concentration of mizoribine. Background technique [0002] Mizoribine (MZR) is a purine nucleoside synthesis inhibitor that can specifically inhibit rapidly growing lymphocytes, resulting in immunosuppressive effects. In recent years, it has been clinically used to inhibit the rejection of kidney transplantation, and also used to treat autoimmune diseases such as lupus nephritis, rheumatoid arthritis and nephrotic syndrome. The pharmacokinetics of this drug vary greatly among individuals, and clinical blood concentration monitoring is required to adjust individualized dosing regimens. [0003] At present, there are only relevant foreign reports on the determination of MZR in biological samples. The existing technical methods have low sensitivity (the lowest limit of q...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Applications(China)
IPC IPC(8): G01N30/02B01J20/281
Inventor 焦正张明钟明康陆福明
Owner AFFILIATED HUSN HOSPITAL OF FUDAN UNIV
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap